Archford Capital Strategies, LLC Bristol Myers Squibb CO Transaction History

Archford Capital Strategies, LLC

  • $681 Million
  • Q3 2024

A detailed history of Archford Capital Strategies, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Archford Capital Strategies, LLC holds 11,806 shares of BMY stock, worth $687,463. This represents 0.09% of its overall portfolio holdings.

Number of Shares
11,806
Previous 11,814 0.07%
Holding current value
$687,463
Previous $490,000 24.49%
% of portfolio
0.09%
Previous 0.08%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024
SELL
$39.66 - $51.75 $317 - $414
-8 Reduced 0.07%
11,806 $610,000
Q2 2024

Jul 17, 2024
SELL
$40.25 - $52.99 $6,882 - $9,061
-171 Reduced 1.43%
11,814 $490,000
Q1 2024

Apr 24, 2024
BUY
$47.98 - $54.4 $6,093 - $6,908
127 Added 1.07%
11,985 $649,000
Q4 2023

Jan 12, 2024
SELL
$48.48 - $57.85 $40,723 - $48,594
-840 Reduced 6.62%
11,858 $608,000
Q3 2023

Oct 27, 2023
SELL
$57.89 - $64.73 $14,993 - $16,765
-259 Reduced 2.0%
12,698 $736,000
Q2 2023

Aug 02, 2023
SELL
$63.71 - $70.74 $24,910 - $27,659
-391 Reduced 2.93%
12,957 $828,000
Q1 2023

Apr 18, 2023
BUY
$65.71 - $74.53 $12,813 - $14,533
195 Added 1.48%
13,348 $925,000
Q4 2022

Jan 26, 2023
BUY
$68.48 - $81.09 $616 - $729
9 Added 0.07%
13,153 $0
Q3 2022

Oct 17, 2022
BUY
$0.13 - $76.84 $13 - $8,068
105 Added 0.81%
13,144 $934,000
Q2 2022

Jul 12, 2022
BUY
$72.62 - $79.98 $145 - $159
2 Added 0.02%
13,039 $1 Million
Q1 2022

Apr 18, 2022
BUY
$61.48 - $73.72 $17,767 - $21,305
289 Added 2.27%
13,037 $970,000
Q4 2021

Jan 20, 2022
SELL
$53.63 - $62.52 $1,394 - $1,625
-26 Reduced 0.2%
12,748 $795,000
Q3 2021

Oct 14, 2021
BUY
$59.17 - $69.31 $7,218 - $8,455
122 Added 0.96%
12,774 $756,000
Q2 2021

Jul 23, 2021
SELL
$61.91 - $67.42 $1,733 - $1,887
-28 Reduced 0.22%
12,652 $845,000
Q1 2021

Apr 26, 2021
SELL
$59.34 - $66.74 $1.13 Million - $1.27 Million
-18,994 Reduced 59.97%
12,680 $817,000
Q4 2020

Jan 19, 2021
SELL
$57.74 - $65.43 $14,377 - $16,292
-249 Reduced 0.78%
31,674 $1.98 Million
Q3 2020

Oct 19, 2020
SELL
$57.43 - $63.64 $55,132 - $61,094
-960 Reduced 2.92%
31,923 $1.93 Million
Q2 2020

Jul 24, 2020
SELL
$54.82 - $64.09 $2,905 - $3,396
-53 Reduced 0.16%
32,883 $1.93 Million
Q1 2020

Apr 29, 2020
BUY
$46.4 - $67.43 $423,446 - $615,366
9,126 Added 38.33%
32,936 $1.84 Million
Q4 2019

Jan 15, 2020
BUY
$49.21 - $64.19 $9,300 - $12,131
189 Added 0.8%
23,810 $1.53 Million
Q3 2019

Oct 23, 2019
SELL
$42.77 - $50.71 $3,720 - $4,411
-87 Reduced 0.37%
23,621 $1.2 Million
Q2 2019

Jul 18, 2019
SELL
$44.62 - $49.34 $1,517 - $1,677
-34 Reduced 0.14%
23,708 $1.08 Million
Q1 2019

May 13, 2019
SELL
$45.12 - $53.8 $4,918 - $5,864
-109 Reduced 0.46%
23,742 $1.13 Million
Q4 2018

Feb 13, 2019
SELL
$48.76 - $63.23 $3,852 - $4,995
-79 Reduced 0.33%
23,851 $1.24 Million
Q3 2018

Nov 14, 2018
SELL
$55.19 - $62.25 $47,297 - $53,348
-857 Reduced 3.46%
23,930 $1.49 Million
Q2 2018

Aug 14, 2018
BUY
$50.53 - $62.98 $56,340 - $70,222
1,115 Added 4.71%
24,787 $1.37 Million
Q1 2018

May 14, 2018
BUY
$59.92 - $68.98 $186,051 - $214,182
3,105 Added 15.1%
23,672 $1.45 Million
Q4 2017

Feb 16, 2018
SELL
$59.94 - $65.35 $237,482 - $258,916
-3,962 Reduced 16.15%
20,567 $1.26 Million
Q3 2017

Nov 17, 2017
BUY
$55.23 - $63.74 $665,852 - $768,449
12,056 Added 96.66%
24,529 $1.56 Million
Q2 2017

Aug 25, 2017
SELL
N/A
-19,183 Reduced 60.6%
12,473 $695,000
Q2 2017

Aug 18, 2017
BUY
N/A
31,656
31,656 $33,000

Others Institutions Holding BMY

# of Institutions
2,533
Shares Held
1.47B
Call Options Held
31.6M
Put Options Held
35M
View Full List

About BRISTOL MYERS SQUIBB CO

BMY Quotes by TradingView
  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $124B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Archford Capital Strategies, LLC Portfolio

Follow Archford Capital Strategies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Archford Capital Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Archford Capital Strategies, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email